Arvinas (ARVN) Capital Expenditures (2017 - 2026)
Arvinas (ARVN) posted quarterly Capital Expenditures of $1.3 million for Q1 2026, up 225.0% year-over-year from $400000.0 in Q1 2025, and up 192.86% quarter-over-quarter from -$1.4 million in Q4 2025.
Analysis
Arvinas (ARVN) Capital Expenditures (2017 - 2026) Analysis & Trends
Arvinas' Capital Expenditures history runs 10 years deep, the most recent figure standing at $1.3 million for Q1 2026.
- In Q1 2026, Capital Expenditures rose 225.0% year-over-year to $1.3 million; the TTM figure through Mar 2026 stood at $1.2 million (down 45.45% YoY), while the FY2025 annual figure was $300000.0, down 83.33% from the prior year.
- Capital Expenditures for Q1 2026 stood at $1.3 million, up from -$1.4 million in the prior quarter.
- The five-year high for Capital Expenditures was $2.1 million in Q1 2022, with the low at -$1.6 million in Q2 2022.
- The 5-year median for Capital Expenditures is $500000.0 (2023), against an average of $400000.0.
- The sharpest annual moves came in 2023 and 2025: Capital Expenditures soared 650.0% in 2023, then slumped 566.67% in 2025.
- Arvinas' Capital Expenditures stood at -$200000.0 in 2022, then soared by 150.0% to $100000.0 in 2023, then surged by 200.0% to $300000.0 in 2024, then plunged by 566.67% to -$1.4 million in 2025, then jumped by 192.86% to $1.3 million in 2026.
- Business Quant data shows ARVN's Capital Expenditures at $1.3 million in Q1 2026, -$1.4 million in Q4 2025, and $100000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | 37.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | 2.29 Mn |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 25.02 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 251.02 Mn |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Arvinas | 605.88 Mn | 37.98 Mn | - | 200,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 200,000.00 |
| Mar 31, 2026 | 1.30 Mn |
| Dec 31, 2025 | 200,000.00 |
| Sep 30, 2025 | 100,000.00 |
| Jun 30, 2025 | 1.20 Mn |
| Mar 31, 2025 | 400,000.00 |
| Dec 31, 2024 | 300,000.00 |
| Sep 30, 2024 | 700,000.00 |
| Jun 30, 2024 | 700,000.00 |
| Mar 31, 2024 | 100,000.00 |
| Dec 31, 2023 | 100,000.00 |
| Sep 30, 2023 | 1.10 Mn |
| Jun 30, 2023 | 600,000.00 |
| Mar 31, 2023 | 1.10 Mn |
| Dec 31, 2022 | 1.10 Mn |
| Sep 30, 2022 | 2.20 Mn |
| Jun 30, 2022 | 1.40 Mn |
| Mar 31, 2022 | 2.10 Mn |
| Dec 31, 2021 | 1.90 Mn |
| Sep 30, 2021 | 1.30 Mn |